JAMA network open

Using Wearable Sensors to Detect Flu and Colds Before Symptoms Appear

Updated

Abstract

Wearable biometric monitoring sensors achieved up to 92% accuracy in detecting presymptomatic H1N1 and rhinovirus infections.

  • Separate detection models for H1N1 and rhinovirus utilized wearable device data to differentiate between infected and non-infected individuals.
  • The H1N1 detection model demonstrated 90% precision, 90% sensitivity, and 93% specificity.
  • The rhinovirus detection model achieved 100% precision and 78% sensitivity.
  • Infection severity prediction models could identify mild and moderate infections 24 hours before symptom onset with 90% accuracy for H1N1.
  • The rhinovirus severity prediction reached 89% accuracy, with 100% precision and 75% sensitivity.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of Interest Disclosures: Dr McClain reported receiving grants from Defense Advanced Research Projects Agency (DARPA) during the conduct of the study; in addition, Dr McClain had a patent for molecular signatures of acute respiratory infections pending. Dr Tsalik reported receiving personal fees from and being the cofounder of Predigen Inc outside the submitted work. Dr Burke reported receiving grants from DARPA during the conduct of the study and serving as a consultant for Predigen Inc outside the submitted work. Dr Turner reported receiving grants from Duke University during the conduct of the study. Dr Chiu reported receiving grants from DARPA during the conduct of the study and grants from Wellcome Trust, Medical Research Council, and the European Commission outside the submitted work. Dr Doraiswamy reported receiving grants from DARPA and nonfinancial support from Lumos Labs during the conduct of the study and receiving grants from Salix, Avanir, Avid, the National Institutes of Health, Cure Alzheimer’s Fund, Karen L. Wrenn Trust, Steve Aoki Foundation, the Office of Naval Research, and the Department of Defense and personal fees from Clearview, Verily, Vitakey, Transposon, Neuroglee, Brain Forum, and Apollo outside the submitted work; in addition, Dr Doraiswamy had a patent for infection detection using wearables pending, a patent for diagnosis of Alzheimer disease pending, a patent for treatment of Alzheimer disease pending, and a patent for infection detection through cognitive variability pending. Dr Ginsburg reported being the founder of Predigen Inc outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free